Cognitive function and platelet membrane fluidity in Alzheimer's disease.
Increased platelet membrane fluidity, as reflected by a decrease in the fluorescence anisotropy of diphenylhexatriene in labeled membranes, identifies a clinically distinct subgroup of approximately 50% of patients at our center who meet NINCDS-ADRDA clinical criteria for Alzheimer's disease. In the current study, we compared the cognitive impairments of patients in this subgroup to those observed in the residual subgroup of patients with Alzheimer's disease who had normal platelet membrane fluidity. No significant differences in the number or distribution of deficits in six cognitive domains were observed between the two subgroups. However, in the subgroup with increased platelet membrane fluidity, there were significantly more patients who exhibited dissociation of deficits on tests related to left and right parietal lobe function than in the residual subgroup. Moreover, the cases with dissociation of deficits consisted almost entirely of patients with deficits on tests reflecting left parietal lobe function and no deficit on tests of right parietal lobe function.
Zubenko
G S
GS
Department of Psychiatry, School of Medicine, University of Pittsburgh, PA.
Huff
F J
FJ
Becker
J
J
Beyer
J
J
Teply
I
I
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood* / Q000503:physiopathology / Q000523:psychology; D001786:Blood Glucose / Q000378:metabolism; D001792:Blood Platelets / Q000502:physiology*; D003072:Cognition Disorders / Q000097:blood* / Q000523:psychology; D004161:Diphenylhexatriene / Q000097:blood; D004292:Dominance, Cerebral / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008560:Membrane Fluidity; D009483:Neuropsychological Tests; D010296:Parietal Lobe / Q000503:physiopathology; D014055:Tomography, Emission-Computed
D001786:Blood Glucose; D004161:Diphenylhexatriene